{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:45:59Z","timestamp":1790117159560,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014630","name":"Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014630","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.euo.2026.01.003","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T14:47:36Z","timestamp":1769093256000},"page":"795-803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic Factors for Overall Survival in the VESPER Trial: Basal Molecular Subtype Is a Relevant Key Factor"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5920-4468","authenticated-orcid":false,"given":"Christian","family":"Pfister","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Harter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Fontugne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Allory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Culine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Flechon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Chevreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Soulie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Mahammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Guy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Laguerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Verhoest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Guillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mottet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Doerfler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Abadie-Lacourtoisie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Azzouzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mongiat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Geoffrois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Eschwege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.Di","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Roubaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Hoepffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Barthelemy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Voog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Mandron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Tourani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Serrrate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Colau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Saldana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"de La Taille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Kleinclauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Irani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Eymard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Larre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Huillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zerbib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Rigaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Houede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Droupy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Malouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.El","family":"Demery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Legon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Vieillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Letang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Lharidon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Gaschignard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Hilgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Davin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.01.003_b0005","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.01.003_b0010","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration","volume":"48","author":"Vale","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.01.003_b0015","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.eururo.2014.01.009","article-title":"Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides","volume":"67","author":"Reardon","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.01.003_b0020","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.eururo.2007.03.086","article-title":"pT0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors","volume":"52","author":"Kassouf","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.01.003_b0025","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2013.06.049","article-title":"Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis","volume":"65","author":"Petrelli","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.01.003_b0030","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.euo.2018.09.004","article-title":"Delaying radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer is associated with adverse survival outcomes","volume":"2","author":"Boeri","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.01.003_b0035","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1080\/21681805.2021.1962403","article-title":"Prediction of neo-adjuvant chemotherapy response in bladder cancer: the impact of clinical parameters and routine biomarkers","volume":"55","author":"Koskinen","year":"2021","journal-title":"Scand J Urol"},{"key":"10.1016\/j.euo.2026.01.003_b0040","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.euf.2020.07.002","article-title":"Nomogram predicting bladder cancer-specific mortality after neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: results of an international consortium","volume":"7","author":"Mir","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2026.01.003_b0045","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/1078-0432.CCR-23-0602","article-title":"Association of molecular subtypes with pathological response, PFS, and OS in a phase II study of COXEN with neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"30","author":"Lerner","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2026.01.003_b0050","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.21.02051","article-title":"Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial","volume":"40","author":"Pfister","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.01.003_b0055","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","article-title":"Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomized, phase 3 study","volume":"25","author":"Pfister","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.01.003_b0060","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/JU.0000000000003836","article-title":"Impact of divergent differentiation and\/or histological subtype of urothelial carcinoma on patient outcomes in the GETUG-AFU V05 VESPER trial","volume":"211","author":"Allory","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.01.003_b0065","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.annonc.2024.09.008","article-title":"Basal\/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial","volume":"36","author":"Groeneveld","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.01.003_b0070","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.24.00340","article-title":"Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274","volume":"43","author":"Galsky","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.01.003_b0075","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"39","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.01.003_b0080","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"Pfister","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.01.003_b0085","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.clgc.2021.08.005","article-title":"Chemotherapy for muscle-invasive bladder cancer: Impact of cisplatin delivery on renal function and local control rate in the randomized phase III VESPER (GETUG-AFU V05) trial","volume":"19","author":"Culine","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2026.01.003_b0090","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1002\/sim.5958","article-title":"Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks","volume":"32","author":"Blanche","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.euo.2026.01.003_b0095","first-page":"65","article-title":"A simple sequentially rejective multiple test procedure","volume":"6","author":"Holm","year":"1979","journal-title":"Scand J Stat"},{"key":"10.1016\/j.euo.2026.01.003_b0100","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BAO6 30894 trial","volume":"29","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.01.003_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104236","article-title":"Predictors of response to neoadjuvant therapy in urothelial cancer","volume":"194","author":"Tripathi","year":"2024","journal-title":"Crit Rev Oncol"},{"key":"10.1016\/j.euo.2026.01.003_b0110","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities tofrontline chemotherapy","volume":"25","author":"ChoiW","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.euo.2026.01.003_b0115","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.01.003_b0120","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1038\/s41467-020-18640-0","article-title":"Molecular correlates of cisplatin based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis","volume":"11","author":"Taber","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2026.01.003_b0125","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.eururo.2021.10.035","article-title":"Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes","volume":"81","author":"Sj\u00f6dahl","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.01.003_b0130","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1158\/1078-0432.CCR-20-2409","article-title":"A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT 02177695)","volume":"27","author":"Flaig","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"Suppl 2","key":"10.1016\/j.euo.2026.01.003_b0135","article-title":"LBA2\u2003Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: the phase III KEYNOTE-905 study","volume":"36","author":"Vulsteke","year":"2025","journal-title":"Ann Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:45:32Z","timestamp":1789577132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126000040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2588931126000040"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.01.003","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Factors for Overall Survival in the VESPER Trial: Basal Molecular Subtype Is a Relevant Key Factor","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}